MECHEM KRISTINE C. 4
4 · OncoCyte Corp · Filed Jun 11, 2018
Insider Transaction Report
Form 4
MECHEM KRISTINE C.
VP of Marketing
Transactions
- Award
Option to Purchase Common Stock
2018-06-07+50,000→ 50,000 totalExercise: $2.85Exp: 2028-06-06→ Common Stock (50,000 underlying)
Holdings
- 67,500
Option to Purchase Common Stock
Exercise: $4.70Exp: 2027-02-16→ Common Stock (67,500 underlying) - 125,000
Option to Purchase Common Stock
Exercise: $2.35Exp: 2028-05-22→ Common Stock (125,000 underlying) - 60,000
Option to Purchase Common Stock
Exercise: $3.06Exp: 2026-02-15→ Common Stock (60,000 underlying) - 100,000
Option to Purchase Common Stock
Exercise: $3.16Exp: 2025-08-03→ Common Stock (100,000 underlying)
Footnotes (5)
- [F1]One half of these options shall vest on the filing of the Medicare dossier for the Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date, and the balance shall vest on the date of return from sabbatical and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date.
- [F2]These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
- [F3]One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- [F4]One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- [F5]One quarter of the options vested on August 3, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.